Literature DB >> 1467389

Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research.

L Hermle1, M Fünfgeld, G Oepen, H Botsch, D Borchardt, E Gouzoulis, R A Fehrenbach, M Spitzer.   

Abstract

The psychological, neuropsychological, and neurometabolic effects of the hallucinogenic agent mescaline were investigated in 12 normal men who were volunteers. Mescaline produced an acute psychotic state 3 1/2-4 hr after drug intake, as measured by the Brief Psychiatric Rating Scale (BPRS) and Paranoid Depression Scale (PDS). The Assessment of Altered States of Consciousness (APZ) questionnaire revealed specific effects of mescaline in the visual system. Neuropsychological effects were studied with a face/nonface decision task with known right-hemisphere advantage, in which mescaline induced a decrease of functioning of the right hemisphere. In functional brain imaging using single photon emission computed tomography (SPECT), mescaline produced a "hyperfrontal" pattern with an emphasis on the right hemisphere, which was correlated with mescaline-induced psychotic psychopathology. Our findings question the validity of the concept of hypofrontality as an explanation for schizophrenic symptomatology. The study of psychoactive substances under controlled laboratory conditions has the methodological advantage of intraindividual control, and hence, minimal variability of data.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467389     DOI: 10.1016/0006-3223(92)90059-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

1.  Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.

Authors:  Jordi Riba; Sergio Romero; Eva Grasa; Esther Mena; Ignasi Carrió; Manel J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2006-03-31       Impact factor: 4.530

2.  Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Authors:  José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2013-06-21       Impact factor: 4.530

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 4.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

Review 5.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 7.  Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.

Authors:  Ricardo Jorge Dinis-Oliveira; Carolina Lança Pereira; Diana Dias da Silva
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

8.  Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

9.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose.

Authors:  Tomás Pálenícek; Marie Balíková; Vera Bubeníková-Valesová; Jirí Horácek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-07       Impact factor: 4.530

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.